Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial

scientific article published on 19 August 2016

Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.IJCARD.2016.08.271
P698PubMed publication ID27589047

P50authorPiotr PonikowskiQ22114836
Gad CotterQ37623977
Beth A. DavisonQ39274037
Marco MetraQ39274051
Douwe PostmusQ58231680
Christopher M O'ConnorQ64689171
Michael M GivertzQ90393574
John R TeerlinkQ90422543
Adriaan A VoorsQ91537232
Biniyam G DemisseiQ91665607
Hans L HillegeQ91827926
Daniel M BloomfieldQ114321740
Howard C DittrichQ114321810
Licette C Y LiuQ114371840
P2093author name stringJohn G Cleland
Christopher Edwards
P407language of work or nameEnglishQ1860
P921main subjectacute decompensated heart failureQ4677930
P304page(s)967-975
P577publication date2016-08-19
P1433published inInternational Journal of CardiologyQ2357863
P1476titleRisk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial
P478volume223

Reverse relations

cites work (P2860)
Q38705811Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure
Q47154474Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan.
Q58102783Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration

Search more.